Axillary radiotherapy for nodal lymphoma: What CTV expansion is required to account for absence of pre-chemotherapy treatment position FDG PET-CT?

Robin Prestwich; Chirag Patel; Andrew Scarsbrook; Viv Cosgrove; Emma Thomas; Di Gilson; David Bird

doi:10.1016/j.ctro.2018.09.003

Axillary radiotherapy for nodal lymphoma: What CTV expansion is required to account for absence of pre-chemotherapy treatment position FDG PET-CT?

Clin Transl Radiat Oncol. 2018 Sep 6:13:14-18. doi: 10.1016/j.ctro.2018.09.003. eCollection 2018 Nov.

Authors

Robin Prestwich¹, Chirag Patel², Andrew Scarsbrook², Viv Cosgrove³, Emma Thomas¹, Di Gilson¹, David Bird³

Affiliations

¹ Clinical Oncology, Bexley Wing, St. James's University Hospital, Leeds Teaching Hospitals Trust, Leeds LS9 7TF, England, UK.
² Radiology and Nuclear Medicine, Bexley Wing, St. James's University Hospital, Leeds Teaching Hospitals Trust, Leeds LS9 7TF, England, UK.
³ Medical Physics and Engineering, Bexley Wing, St. James's University Hospital, Leeds Teaching Hospitals Trust, Leeds LS9 7TF, England, UK.

Abstract

Involved site lymphoma radiotherapy clinical target volumes (CTV) require expansion in the absence of treatment-position pre-chemotherapy PET-CT. This prospective imaging study evaluates CTV contouring for axillary lymphoma using diagnostic imaging compared with co-registered treatment-position PET-CT. Generous expansion axially and cranio-caudally is required to encompass pre-chemotherapy disease without treatment-position pre-chemotherapy PET-CT.

Keywords: Axilla; Clinical target volume; Lymphoma; PET-CT; Radiotherapy.